Results 121 to 130 of about 3,081 (193)

Real-World Treatment Patterns for Waldenstrom Macroglobulinemia: Implications for Treatment Sequencing. [PDF]

J Korean Med Sci
Jang SY, Byun JM, Park SS, Kim Y, Park J, Shin DY, Koh Y, Kim I, Min CK, Yoon SS.   +9 more
europepmc   +1 more source

Treatment patterns in relapsed/refractory marginal zone lymphoma: real-world evidence from seven countries. [PDF]

Future Oncol
Patel H, Huynh L, Squires P, Prescott J, Ryland K, Catillon M, Guo T, Tamakloe K, Liu S, Duh MS, Raut M, Portell CA.   +11 more
europepmc   +1 more source

Clinical Impact of BTK Inhibitor Exposure in LymphGen-Defined MCD Diffuse Large B-Cell Lymphoma. [PDF]

Hematol Oncol
Jiang S, Liu Y, Wei R, Zhang W, Bao L, Jin J, Lv F, Liu C, Liu X, Sun H, Wang J, Tao R, Cao J, Zhou X, Zhang Q.   +14 more
europepmc   +1 more source

Treatment, Monitoring, and Management of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Evidence From a Multi-Country Needs Assessment. [PDF]

Cancer Rep (Hoboken)
Lazure P, Eyre TA, Niemann CU, Shah NN, Dreyling M, Cymbalista F, Peloquin S, Znamensky S, Goebel B, Murray S.   +9 more
europepmc   +1 more source

Continuous or fixed-duration BTK inhibitor treatment for WM. [PDF]

Blood Adv
Yi S, Qiu L.
europepmc   +1 more source

Cellular therapy in mantle cell lymphoma: recommendations from the EBMT practice harmonisation and guidelines committee. [PDF]

Bone Marrow Transplant
Dreger P, Iacoboni G, Robinson S, Bazarbachi A, Dietrich S, Eyre TA, Ahmed S, Fenske TS, Ghosh N, Hamadani M, Onida F, Ruggeri A, Ortega-Sanchez I, Yakoub-Agha I, Hermine O.   +14 more
europepmc   +1 more source

Comparative atrial fibrillation risk across Bruton's tyrosine kinase inhibitors in B-cell malignancies: A nationwide population-based study. [PDF]

Br J Haematol
Zelmat Y, Ysebaert L, Gautier P, Sommet A, Lafaurie M, Despas F.   +5 more
europepmc   +1 more source

Comparison of Venetoclax-Based Treatments for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: A Single-Center Real-World Experience. [PDF]

EJHaem
Heyman B, Choi M, Kipps TJ.
europepmc   +1 more source

Efficacy and safety analysis of a novel BTK inhibitor in patients with mantle cell lymphoma harboring TP53 mutations. [PDF]

Am J Cancer Res
Liu M, Ding Y, Lan H.
europepmc   +1 more source

Trials in progress: CARMAN - study protocol of a randomized controlled, international, multicenter, open-label phase II trial evaluating early treatment intensification in patients with high-risk mantle cell lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with rituximab and ibrutinib and 6 months ibrutinib maintenance as compared to standard of care induction and maintenance. [PDF]

BMC Cancer
Tilch MK, Schmidt C, Trneny M, Giné E, Hermine O, Ohler A, Herold S, Hoster E, Jiang L, Pott C, Dreyling M, Hess G.   +11 more
europepmc   +1 more source